Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (September 2011)
15 slides from Oncolytics Biotech's investor presentation, September 2011
Slide 1: Forward Looking Statements
TSX:ONC NASDAQ:ONCY September 2011 Forward Looking Statements Today’s presentation contains certain forward looking statements relating to the company’s financial results, business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on
Slide 2: Summary: REOLYSIN - A Broadly Active Novel Cancer Therapy
Summary REOLYSIN - A Broadly Active Novel Cancer Therapy Focused Clinical Program • Lead product is REOLYSIN® • Phase III REOLYSIN and paclitaxel/carboplatin in platinum-refractory head and neck cancer patients (international study) • Randomized Phase II REOLYSIN and paclitaxel in ovarian and reprod
Slide 3: REOLYSIN Pipeline and Pivotal Phase III Program
REOLYSIN Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Head & neck (REO 018) in combination with carboplatin + paclitaxel Recurrent ovarian, fallopian tube, or primary peritoneal in combination with paclitaxel (randomized, GOG-0186H) NSCLC (Kras screened) (REO 016) in combination with carb
Slide 4: Interim Results Compared to Historical Controls
Interim Results Compared to Historical Controls Second-Line Other Therapies in Platinum Refractory Patients Study Reference Response Rate Median TTP Median Survival or PFS (months) (months) Various treatments or Léon et al., 2005 2.6% No Data 3 Best Supportive care Docetaxel Specenier et al., 6.7% <
Slide 5: Phase II REOLYSIN/Paclitaxel/Carboplatin Combination Metastatic Nasopharyngeal
Phase II REOLYSIN/Paclitaxel/Carboplatin Combination Metastatic Nasopharyngeal Pre-treatment Post cycle 3 prior treatment results • radiation - 2 cycles • target lesion - liver metastases • cisplatin, gemcitabine/carboplatin, • baseline - 59.4 mm carboplatin/5-FU - 6 cycles • post cycle 3-19 mm • do
Slide 6: UK Phase II REOLYSIN/Carbo/Taxol Combination Partial Response
UK Phase II REOLYSIN/Carbo/Taxol Combination Partial Response in Poorly Differentiated SCC H&N Pre-treatment Post Cycle 3 Treatment history: palliative RT cisplatin + 5FU carboplatin + 5FU UK Phase II REOLYSIN/Carbo/Taxol Combination Partial Response in SCC H&N Pre-treatment Rapid After 3 cycles pro
Slide 7: US Phase 2 Ovarian: REOLYSIN/Paclitaxel Combination
REOLYSIN Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Head & neck (REO 018) in combination with carboplatin + paclitaxel Recurrent ovarian, fallopian tube, or primary peritoneal in combination with paclitaxel (randomized, GOG-0186H) NSCLC (Kras screened) (REO 016) in combination with carb
Slide 8: Phase II Studies of REOLYSIN in Pancreatic Cancer
REOLYSIN Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Head & neck (REO 018) in combination with carboplatin + paclitaxel Recurrent ovarian, fallopian tube, or primary peritoneal in combination with paclitaxel (randomized, GOG-0186H) NSCLC (Kras screened) (REO 016) in combination with carb
Slide 9: Pancreatic Cancer and Ras Pathway Activation
Pancreatic Cancer and Ras Pathway Activation - US Phase 2 Pancreatic Cancer REOLYSIN/Gemzar Combination - PR in Hepatic Hilar Lymph Node and Pancreatic Head Pre treatment Post cycle 1 REOLYSIN Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Head & neck (REO 018) in combination with carboplat
Slide 10: Phase II NSCLC and Kras/EGFR
US Phase 2 SCCLC: REOLYSIN/Carbo/Taxol Combination Pt 0001 – Partial Response (PR) in Lung Pre-treatment Post 2 Cycles Post 4 Cycles Right Upper Lung Mass (8.3 cm) Right Upper Lung Mass (4.1cm) Right Upper Lung Mass (3.6cm) Right pleural met (2.2cm) Right pleural met (0.8cm) Right pleural met (0.4cm
Slide 11: US Phase NSCLC: Partial Response in Lung
US Phase 2 NSCLC US Phase 2 NSCLC: REOLYSIN/Carbo/Taxol Combination - Partial Response (PR) in Lung by CT (EGFR Mutation) Pretreatment Post Cycle 2 • FISH for EGFR (Red) and CEP7 (Green) • Ex19 18bp in-frame deletion and T790M mutation REOLYSIN Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3
Slide 12: Colorectal Cancer and Kras; Safety
Colorectal Cancer and Kras • current standard of care for second-line patients also includes EGFR inhibitors • 45% of second-line colorectal patients have Kras mutations • Phase I study of 12-20 patients using REOLYSIN/FOLFIRI combination in second line patients prescreened for Kras mutations • tran
Slide 13: Intellectual Property and Manufacturing
Intellectual Property • more than 250 patents issued worldwide including 43 U.S. and 11 CDN • reovirus issued p patent claims cover - compositions of matter comprising reovirus - pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases - combination therapy with radiat
Slide 14: Market & Capital Data
Market & Capital Data Exchanges NASDAQ:ONCY TSX:ONC Shares Outstanding (June 30, 2011) 71,209,164 Warrants Expiring Price Nov 8, 2012 $6.15 1,794,750 Nov 8, 2012 $4.60 375,360 Options $4.51 (average) 4,630,094 Fully Diluted (June 30, 2011) 78,009,368 Est. Cash/Cash Equivalents $46.6 M (June 30, 2011
Slide 15: September 2011
TSX:ONC NASDAQ:ONCY September 2011
Oncolytics Biotech — Investor Presentation (September 2011) on 6ix